⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALMS News
Alumis Inc. Common Stock
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
globenewswire.com
ALMS
Alumis to Participate in Upcoming September Investor Conferences
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Form 8-K
sec.gov
ALMS